Analyzing Cost of Revenue: United Therapeutics Corporation and Amphastar Pharmaceuticals, Inc.

Biopharma Cost Trends: A Decade of Growth and Strategy

__timestamp	Amphastar Pharmaceuticals, Inc.	United Therapeutics Corporation
Wednesday, January 1, 2014	159205000	125883000
Thursday, January 1, 2015	174172000	69036000
Friday, January 1, 2016	150976000	72700000
Sunday, January 1, 2017	149380000	105700000
Monday, January 1, 2018	187681000	198700000
Tuesday, January 1, 2019	190434000	117600000
Wednesday, January 1, 2020	206506000	108100000
Friday, January 1, 2021	238029000	122500000
Saturday, January 1, 2022	250127000	146700000
Sunday, January 1, 2023	293274000	257500000

Unveiling the hidden dimensions of data

Analyzing Cost of Revenue Trends in Biopharmaceuticals

In the ever-evolving landscape of biopharmaceuticals, understanding cost dynamics is crucial. This analysis delves into the cost of revenue trends for United Therapeutics Corporation and Amphastar Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Amphastar Pharmaceuticals saw a remarkable 84% increase in its cost of revenue, peaking at approximately $293 million in 2023. Meanwhile, United Therapeutics experienced a 105% surge, reaching around $258 million in the same year.

Key Insights

Amphastar Pharmaceuticals: The company maintained a steady upward trajectory, with costs rising consistently year-over-year, reflecting its expanding operations and market reach.
United Therapeutics: Despite fluctuations, the company showed a significant increase in 2023, indicating strategic investments or scaling efforts.

These trends highlight the dynamic nature of the biopharmaceutical industry, where strategic financial management is key to sustaining growth and innovation.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025

Similar Statistics

Cost Insights: Breaking Down Eli Lilly and Company and Amphastar Pharmaceuticals, Inc.'s Expenses

Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and United Therapeutics Corporation

Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses

Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.

United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored

Cost Insights: Breaking Down United Therapeutics Corporation and Alkermes plc's Expenses

Cost of Revenue Trends: United Therapeutics Corporation vs PTC Therapeutics, Inc.

Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Amphastar Pharmaceuticals, Inc.

Cost Insights: Breaking Down Grifols, S.A. and Amphastar Pharmaceuticals, Inc.'s Expenses

Comparing Cost of Revenue Efficiency: Vericel Corporation vs Amphastar Pharmaceuticals, Inc.

Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses